It remains to be determined whether GLP-1 receptor agonist therapies are more effective in patients with hyperinsulinemia, or to what extent the benefits are due to reducing body weight and ameliorating obesity-related comorbidities of PCOS. Here, GLP1R is linked to polycystic ovary syndrome.